A method for identifying a Shenqi Fuzheng injection fingerprint profile by ultra-high pressure liquid chromatography-mass spectrometry, comprising the following steps: step: establishing a profile of the samples to be tested; step: establishing a characteristic fingerprint profile of Shenqi Fuzheng injection as the standard fingerprint profile; step: comparing the profile of the samples to be tested in step with the standard fingerprint profile in step to distinguish between real and fake; wherein, the standard fingerprint profile in step comprises 18 characteristic peaks, and the retention time and the mass number of the 18 characteristic peaks are as follows: Peak 1: 7.1 min (471.2083), Peak 2: 7.5 min (491.1195), Peak 3: 8.1 min (441.1919), Peak 4: 8.6 min (309.1555), Peak 5: 9.2 min (187.0976), Peak 6: 9.9 min (441.1766), Peak 7: 10.9 min (593.1876), Peak 8: 11.3 min (507.1508), Peak 9: 11.7 min (463.1610), Peak 10: 12.7 min (991.5119), Peak 11: 13.4 min (991.5119), Peak 12: 13.7 min (829.4591), Peak 13: 14.4 min (871.4697), Peak 14: 14.8 min (871.4697), Peak 15: 15.1 min (871.4697), Peak 16: 15.5 min (913.4650), Peak 17: 15.9 min (913.4650), Peak 18: 16.3 min (913.4650); wherein Peak 2 and Peak 12 are calycosin glucoside and astragaloside IV, respectively; wherein the method further comprises taking the control astragaloside IV as a reference peak of the Shenqi Fuzheng injection characteristic fingerprint profile, and calculating the relative retention time of each characteristic peak, as follows: Peak 1: 0.52, Peak 2: 0.54, Peak 3: 0.59, Peak 4: 0.62, Peak 5: 0.66, Peak 6: 0.72, Peak 7: 0.79, Peak 8: 0.82, Peak 9: 0.85, Peak 10: 0.92, Peak 11: 0.97, Peak 12: 1.00, Peak 13: 1.04, Peak 14: 1.07, Peak 15: 1.10, Peak 16: 1.13, Peak 17: 1.16, Peak 18: 1.19; wherein, when comparing, the relative retention time fluctuates within ±5% of the above specified values, and the ratio of the area of the calycosin glucoside peak and the astragaloside IV peak to the area of the corresponding reference peak is 0.5-1.5. step: establishing a profile of the samples to be tested; step: establishing a characteristic fingerprint profile of Shenqi Fuzheng injection as the standard fingerprint profile; step: comparing the profile of the samples to be tested in step with the standard fingerprint profile in step to distinguish between real and fake; Peak 1: 7.1 min (471.2083), Peak 2: 7.5 min (491.1195), Peak 3: 8.1 min (441.1919), Peak 4: 8.6 min (309.1555), Peak 5: 9.2 min (187.0976), Peak 6: 9.9 min (441.1766), Peak 7: 10.9 min (593.1876), Peak 8: 11.3 min (507.1508), Peak 9: 11.7 min (463.1610), Peak 10: 12.7 min (991.5119), Peak 11: 13.4 min (991.5119), Peak 12: 13.7 min (829.4591), Peak 13: 14.4 min (871.4697), Peak 14: 14.8 min (871.4697), Peak 15: 15.1 min (871.4697), Peak 16: 15.5 min (913.4650), Peak 17: 15.9 min (913.4650), Peak 18: 16.3 min (913.4650); wherein Peak 2 and Peak 12 are calycosin glucoside and astragaloside IV, respectively; wherein the method further comprises taking the control astragaloside IV as a reference peak of the Shenqi Fuzheng injection characteristic fingerprint profile, and calculating the relative retention time of each characteristic peak, as follows: Peak 1: 0.52, Peak 2: 0.54, Peak 3: 0.59, Peak 4: 0.62, Peak 5: 0.66, Peak 6: 0.72, Peak 7: 0.79, Peak 8: 0.82, Peak 9: 0.85, Peak 10: 0.92, Peak 11: 0.97, Peak 12: 1.00, Peak 13: 1.04, Peak 14: 1.07, Peak 15: 1.10, Peak 16: 1.13, Peak 17: 1.16, Peak 18: 1.19; wherein, when comparing, the relative retention time fluctuates within ±5% of the above specified values, and the ratio of the area of the calycosin glucoside peak and the astragaloside IV peak to the area of the corresponding reference peak is 0.5-1.5. Peak 1: 0.52, Peak 2: 0.54, Peak 3: 0.59, Peak 4: 0.62, Peak 5: 0.66, Peak 6: 0.72, Peak 7: 0.79, Peak 8: 0.82, Peak 9: 0.85, Peak 10: 0.92, Peak 11: 0.97, Peak 12: 1.00, Peak 13: 1.04, Peak 14: 1.07, Peak 15: 1.10, Peak 16: 1.13, Peak 17: 1.16, Peak 18: 1.19; wherein, when comparing, the relative retention time fluctuates within ±5% of the above specified values, and the ratio of the area of the calycosin glucoside peak and the astragaloside IV peak to the area of the corresponding reference peak is 0.5-1.5.